UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 175 filers reported holding UNIQURE NV in Q1 2022. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $36 | -12.2% | 1,834 | 0.0% | 0.00% | – |
| Q4 2022 | $41 | -100.0% | 1,834 | -94.3% | 0.00% | -100.0% |
| Q3 2022 | $607,000 | -64.6% | 32,384 | -64.8% | 0.00% | -66.7% |
| Q2 2022 | $1,715,000 | -13.3% | 91,998 | -16.0% | 0.01% | +12.5% |
| Q1 2022 | $1,978,000 | +760.0% | 109,473 | +884.4% | 0.01% | +700.0% |
| Q4 2021 | $230,000 | -87.0% | 11,121 | -80.0% | 0.00% | -85.7% |
| Q3 2021 | $1,774,000 | +1243.9% | 55,500 | +889.3% | 0.01% | +600.0% |
| Q1 2018 | $132,000 | -70.7% | 5,610 | -88.1% | 0.00% | -50.0% |
| Q3 2017 | $451,000 | -57.0% | 47,023 | -74.9% | 0.00% | -60.0% |
| Q4 2016 | $1,049,000 | +30.5% | 187,476 | +71.9% | 0.01% | +25.0% |
| Q2 2016 | $804,000 | -22.8% | 109,033 | +182.6% | 0.00% | -20.0% |
| Q2 2015 | $1,041,000 | +468.9% | 38,585 | +413.8% | 0.01% | +400.0% |
| Q1 2015 | $183,000 | +86.7% | 7,510 | +19.6% | 0.00% | 0.0% |
| Q1 2014 | $98,000 | – | 6,278 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |